Risk Reduced Drug Development

SynDevRx™, Inc. is a translational drug development company. Our mission is to develop promising therapeutics which pass our proprietary screening process through clinical proof of concept, and then sell them to large pharmaceutical partners.

The first two drugs to be developed were invented by premier scientists at Children’s Hospital Boston (CMCC) under the direction of Dr. Judah Folkman: Caplostatin™ ( lead - intravenous) and Lodamin™ (follow-on - oral) are drugs with anti-angiogenic, anti-metastatic and anti-proliferative activity suitable to treat cancer patients.

These first two nanoparticle based therapies are novel polymeric compounds that inhibit an enzyme which regulates overexpressed proteins and signaling pathways key to improper cell proliferation.  Inhibiting this activity is expected to provide therapeutic benefit in many cancer indications including;

   •  NSCLC,

   •  colon (CRC),

   •  ovarian,

   •  breast (metastatic),

   •  prostate, and

   •  bladder (TCC) .

Technical risk is reduced since functional parts of our polymeric nanomedicines are well characterized with many years of supportive research.  The active ingredient has clinically demonstrated anti-tumor activity in many tumor types including non-small cell lung, metastatic breast, ovarian, cervical, colon, melanoma, among others. Patents have recently issued covering the core elements of our program.

Based on our timeline, we expect to be in clinical trials in 18 months with our lead drug.